Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...

Shares of VCYT have been moving higher over the past four weeks, up 41.7%. Plus, the company is currently a #1 (Strong Buy) on the Zacks Rank, suggesting that VCYT could be poised for a breakout.

Veracyte, Inc. (NASDAQ:VCYT) generated revenue of $114.5 million in the first quarter of fiscal 2025, marking a 18% increase from last year’s comparable quarter.

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

Veracyte VCYT is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The company’s Decipher franchise continues to be a strong tailwind, with ...

Veracyte, Inc. (NASDAQ:VCYT) has a market capitalization of $1.553 billion. NCG Micro-Cap Strategy stated the following regarding Veracyte, Inc. (NASDAQ:VCYT) in its fourth quarter 2023 investor ...

Investors in Veracyte Inc (Symbol: VCYT) saw new options begin trading this week, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCYT ...